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Background: Until now, cell therapy has constituted a passive therapeutic approach; the only effects seem to be
related to the reduction of the myocardial fibrosis and the limitation of the adverse ventricular remodeling. Cardiac
resynchronization therapy is indicated in patients with heart failure to correct conduction disorders associated
with chronic systolic and diastolic dysfunction. The association of electrostimulation with cellular cardiomyo-
plasty could be a way to transform passive cell therapy into ‘‘dynamic cellular support.’’ Electrostimulation of
ventricles following skeletal myoblast implantation should induce the contraction of the transplanted cells and
a higher expression of slow myosin, which is better adapted for chronic ventricular assistance. The purpose of
this study is to evaluate myogenic cell transplantation in an ischemic heart model associated with cardiac resynch-
ronization therapy.
Methods: Twenty two sheep were included. All animals underwent myocardial infarction by ligation of 2 cor-
onary artery branches (distal left anterior descending artery and D2). After 4 weeks, autologous cultured myo-
blasts were injected in the infarcted areas with or without pacemaker implantation. Atrial synchronized
biventricular pacing was performed using epicardial electrodes. Echocardiography was performed at 4 weeks
(baseline) and 12 weeks after infarction.
Results: Echocardiography showed a significant improvement in ejection fraction and limitation of left ventric-
ular dilatation in cell therapy with cardiac resynchronization therapy as compared with the other groups. Viable
cells were identified in the infarcted areas. Differentiation of myoblasts into myotubes and enhanced expression of
slow myosin heavy chain was observed in the electrostimulated group. Transplantation of cells with cardiac re-
synchronization therapy caused an increase in diastolic wall thickening in the infarcted zone relative to cells-only
group and cardiac resynchronization therapy–only group.
Conclusions: Biventricular pacing seems to induce synchronous contraction of transplanted myoblasts and the
host myocardium, thus improving ventricular function. Electrostimulation was related with enhanced expression
of slow myosin and the organization of myoblasts in myotubes, which are better adapted at performing cardiac
work. Patients with heart failure presenting myocardial infarct scars and indication for cardiac resynchronization
therapy might benefit from simultaneous cardiac pacing and cell therapy.Cell transplantation for cardiac support and regeneration
may repair the injured heart but is limited by poor effect
in systolic function. This can be due to the lack of gap junc-
tions between the native myocardium and the grafted cells.
Also, cell transplantation seems to be limited by death of
transplanted cells.1-4 Most cell death occurs in the first
few days posttransplantation, likely from a combination
of ischemia, anoikis, and inflammation. Anoikis is a form
of apoptosis that is induced by anchorage-dependent cells
detaching from the surrounding extracellular matrix.
Interventions known to enhance transplanted cell survival
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free radical scavengers, anti-inflammatory therapy, and co-
delivery of extracellular matrix molecules. Combinatorial
use of such interventions could enhance graft cell survival.5
Despite these possibilities, until now cell transplantation
has constituted a passive therapeutic approach; the only
effects seem to be related to the reduction of the myocardial
fibrosis and the limitation of the adverse ventricular remod-
eling.6,7
Atrial synchronized biventricular pacing for cardiac
resynchronization therapy (CRT) is indicated in patients
with heart failure to correct conduction disorders associated
with chronic systolic and diastolic dysfunction.8-10 The
association of electrostimulation with cellular cardiomyo-
plasty could be a way to transform passive cell therapy
into ‘‘dynamic cellular support.’’ The principles of electro-
physiologic conditioning of skeletal muscle fibers (eg, as
developed for dynamic cardiomyoplasty procedure) can be
applied in cellular cardiomyoplasty.11 The hypothesis is
that electrostimulation of both ventricles following skeletalgery c October 2009
Shafy et al Evolving Technology/Basic Science
E
T
/B
SAbbreviations and Acronyms
CRT ¼ cardiac resynchronization therapy
DAPI ¼ 40,6-diamidino-2-phenylindole
LV ¼ left ventricular
LVEDV ¼ left ventricular end-diastolic volume
myoblast implantation should induce the contraction of the
transplanted cells and a higher expression of slow myosin,
which is better adapted for chronic ventricular assistance.
The purpose of this study is to evaluate myogenic cell trans-
plantation in an ischemic heart model12,13 associated with
atrial synchronized biventricular pacing.
MATERIALS AND METHODS
Experimental Animals
In 22 female Rambouillet sheep weighing 21 to 34 kg (mean, 30  3.5
kg), a left ventricular (LV) myocardial infarct was surgically created by
ligation of 2 coronary artery branches (distal left anterior descending
artery and D2). During the procedure, a skeletal muscle biopsy was
performed.
Four weeks after coronary artery ligation, 4 different treatment groups
were defined: group 1 (control, n¼ 5): surgical injection of cell culture me-
dium in the infarcted area; group 2 (cell therapy, n¼ 5): intrainfarct implan-
tation of autologous myoblasts (70 million cells); group 3 (CRT, n ¼ 5):
biventricular cardiac pacing alone; group 4 (cellsþCRT, n¼ 5): intrainfarct
implantation of myoblasts associated with cardiac pacing.
In the CRT group, atrial synchronized biventricular pacing using epicar-
dial electrodes was performed after cell implantation (study design in
Figure 1).
All animals were treated according to the guidelines of the French
National Institute of Health and Medical Research (INSERM).
Anesthetic Management
Premedication was carried out by intramuscular injection of aceproma-
zine (Vetranquil; Sanofi, Paris, France) 150 mg. The animals were pre-
pared for surgery, using a jugular venous line and an auricular arterial
line. For anesthesia, propofol (Diprivan; AstraZeneca, Rueil-Malmaison,
France) was administered though the venous line at a concentration of
6 mg/kg. Ventilation was ensured though an endotracheal probe (No. 7)
connected to a Siemens 900C respirator (Siemens AG, Munich, Germany)
using the following parameters: volume of 10 mL/kg, frequency of 24
breaths/min, and inspired oxygen fraction of 60%. Anesthesia was main-
tained by inhalation of isoflurane 1% to 2%. Postoperative management
of the sheep consisted of cefazolin injected intramuscularly at 1 g per day
during 5 days.
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FIGURE 1. Study design. MI, Myocardial infarction.The Journal of Thoracic and CSkeletal Muscle Explantation and Myocardial
Infarction
A 2-cm3 skeletal muscle fragment was taken from the left posterior fem-
oral biceps of each sheep under sterile conditions. The biopsy tissue was
kept in Hanks balanced salt solution (Life Technologies, Rockville, Md)
at 4C until the cell culture was started.
Via a left thoracotomy, the ligation of the distal homonymous (equiv-
alent to human left anterior descending) and second diagonal coronary
arteries produced a constant transmural myocardial infarction (Figure 2).
To reduce the risk of ventricular fibrillation, lidocaine 1% (2 mg $ kg1
$ h1) was administered intravenously during the entire surgical proce-
dure. Thereafter, the thoracic wall was closed after placing a chest
tube in the pleural cavity. The drain was removed as soon as the sheep
started spontaneous respiration. The severity of the myocardial injury
was evaluated by cardiac troponin I serum levels measured 24 hours
after infarction.
Satellite Cell Isolation and Culture
Skeletal myoblasts obtained from autologous muscle biopsy samples
were isolated, purified, and cultured as previously described.7 In brief, the
cells were cultured for 4 weeks in Ham’s F12 medium containing 20% fetal
calf serum and 1% penicillin/streptomycin. To reduce the number of fibro-
blasts and achieve a pure myoblast culture, a preplating step was applied on
the first passage. The preplating technique was based on the quicker attach-
ment of fibroblasts compared with satellite cells. At 4 weeks, the cultured
myoblasts were detached from the cell culture dish with 0.25% trypsin-
ethylenediaminetetraacetic acid. After centrifugation at 300g for 5 minutes,
70 million cells were resuspended in 2 mL of culture medium and used for
each transplantation (Figure 3, A–C).
Cell Labeling
Sterile 40,6-diamidino-2-phenylindole (DAPI) stock solution (Sigma, St
Louis, Mo) was added to the culture medium at a final concentration of
50 mg/mL on the day of implantation. The dye was allowed to remain in
the culture dishes for at least 30 minutes. The cells were rinsed at least 6
times in Hanks balanced salt solution to remove all excess (unbound)
DAPI. Myoblast cells were then collected (approximately 70 3 106 cells
for 1 implantation) and resuspended in minimal volume of the serum-free
Dulbecco’s medium and stored on ice (less than 1 hour) until implantation
into the myocardium.
FIGURE 2. Explanted heart at 12 weeks of myocardial infarction, created
by the ligation of the distal homonymous (equivalent to human left anterior
descending) and second diagonal coronary arteries. View from the apex of
the right ventricle (RV), the left ventricle (LV), and the myocardial infarction
(MI).ardiovascular Surgery c Volume 138, Number 4 995
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SFIGURE 3. A, Skeletal myoblasts after 4 weeks of in vitro culture (phase contrast, magnification 3100). B, The red asterisk shows cells that appear with
a typical myoblast phenotype. The black asterisks show cells proliferating toward a myotube-like shape (magnification 3400). C, The arrows show nuclei
with different morphology, from central round to peripheral elongated corresponding to different stages of skeletal muscle differentiation (magnification
31000).Cell Implantation
After a 4-week in vitro cell expansion period, the animals were oper-
ated on. After usual preparation and median sternotomy, the infarct area
was identified and the cell suspension was injected by using an insulin sy-
ringe and a retrobulbar ophthalmic needle (25 gauge 3 40 mm). By 4 in-
jection points, 70% of cells were implanted in the peri-infarct area (border
zone), as residual irrigation and collateral myocardial revascularization in
this intermediate area allows for a better survival of the implanted cells.
The remaining 30% of cells were implanted in the central portion of
the scar. The treated area was identified with 2 single sutures associated
with metal ligating clips. The use of a long needle for cell implantation
avoids multiple traumatic injection points. Cells were delivered when
the implanted needle was progressively removed from the myocardium.
To avoid regurgitation of the cell solution (channel leakage), we per-
formed finger compression (1 to 2 minutes) at the needle injection sites
after every injection.
Pacemaker Implantation
Animals were implanted with a pulse generator, Transform device
(Model 4710, Medtronic, Minneapolis, Minn), which is an implantable
programmable dual-channel pacemaker with the 2 channels coordinated
by a synchronization circuit. The first channel is capable of sensing atrial
signals and delivering stimuli to them when the sensed atrial intrinsic rate
drops below the programmed pacing rate. The second channel is capable
of generating a stimulation pulse synchronized to the first channel. The syn-
chronization circuit determines the synchronization of the ventricles to
paced or sensed atrial events.
Four epicardial electrodes (Medtronic SP 5591) were used for every
sheep: 2 were implanted in the right atrium, 1 in the right ventricle, and 1
in the left ventricle near the infarcted area.
Stimulation protocol was done by sensing of the right atrium and biven-
tricular pacing using an atrioventricular delay of 70 ms (the normal delay at996 The Journal of Thoracic and Cardiovascular Surrest in sheep is 110 ms). This approach was used to induce the capture of
ventricular activity. Atrial synchronized biventricular pacing was performed
using the epicardial ventricular electrodes, with single pulses (amplitude of
5 V and a pulse width of 0.5 milliseconds).
Evaluation of Ventricular Function
Echocardiography (Sonos 1000, Hewlett-Packard, Palo Alto, Calif) with
the aid of a 7-MHz transducer in the epicardial positionwas performed at cell
implantation or at control medium injection or pacemaker implantation.
Echocardiography was performed before infarction (preischemic), 4 weeks
after infarction, and at 12 weeks after infarction. The global cardiac function
wasmeasured at the same time points in the 2-dimensionalmode. Parameters
included the LV end-diastolic and end-systolic diameters, the shortening
fraction, the end-diastolic and systolic volumes, and the ejection fraction.
The ejection fraction and shorteningwere calculated by the Teicholzmethod
and were based on the LV end-systolic and end-diastolic diameters.
Histology and Immunohistochemistry
All sheep were killed 12 weeks after creation of infarct. The site of myo-
cardial injury was identified and dissected. Five specimens were harvested,
and each of these was cut into 2 pieces. The first piece was fixed in 10%
formol, embedded in paraffin, and sectioned to yield 10-mm-thick slices.
The sections were stained with hematoxylin and eosin. The second piece
of each specimen was frozen in liquid nitrogen–cooled isopentane. Frozen
biopsy tissue was stored at80C until it was processed on a cryostat.
When cells were observed in the infarct sections, they were tested with
fast and slow myosin heavy chain antibodies (Sigma Aldrich, St Louis,
Mo),which are specific for the skeletal isoformof adult fast and slowmyosin.
For immunohistochemical studies, 5-mm-thick sections of frozen tissues
were fixed for 10 minutes in cold acetone, and endogenous avidin and biotin
sites were blocked (Dako, Glostrup, Denmark). Samples were incubated
with the myosin heavy chain antibodies (1:300) in 0.1% fetal calf serumgery c October 2009
Shafy et al Evolving Technology/Basic Sciencefor 1 hour, followed by incubation with biotinyl anti-mouse immunoglobu-
lin (1:200) (Vector Laboratories, Burlingame, Calif), and finally were
incubated with streptavidin-cyanine 2 (Amersham Biosciences, Bucking-
hamshire, UK) 1:800 in phosphate-buffered saline for 30 minutes. The
slides were then mounted with the Immuno-mount system (Thermo Shan-
don, Runcorn, UK) and studied with an inverted fluorescent microscope
(Nikon Eclipse TE300; Nikon Inc, Melville, NY).
Statistical Methods
Results are reported as percentage or mean  standard deviation. A
paired or unpaired Student t test was used to compare the groups when
needed. A 1-way analysis of variance was used when more than 2 groups
were present. When indicated, a Student-Newman-Keuls multiple compar-
ison test was used as a post hoc test.
RESULTS
Myocardial Infarction Creation
Of 22 operated animals, 2 died during the creation of the
infarction; both developed refractory ventricular fibrillation.
Cardiac troponin I was chosen as an indicator of myocardial
infarction. Cardiac troponin I values were expressed as mean
 standard deviation. The average serum level of cardiac
troponin I 1 day after infarction was 125.4  70 ng/mL.
No mortality was registered during reoperations or follow-
up; at 12 weeks, there were 20 surviving animals (5 in
each group).
Cell Cultures
Cell culture conditions were evaluated before cell implan-
tation; the primary skeletal muscle cell culture contained
about 90% myoblasts as determined with desmin immuno-
fluorescence. All cultures showed 99% viability before
implantation by means of trypan blue exclusion assay. In ad-
dition, all cell culture media taken from the cultures before
implantation tested negative for aerobic and nonaerobic bac-
terial contaminations.
Echocardiography
LV function and dimensions were quantified 4 (baseline)
and 12 weeks after myocardial injury. At baseline, the mean
ejection fraction and left ventricular end-diastolic volume
(LVEDV) were similar in all 4 treatment groups (Table 1).
Over the course of 4 weeks, each group dilated their LV
end-diastolic dimension compared with their preoperative
value. At 12 weeks, a statistically significant attenuation of
LV dilation was demonstrated with CRTþ cells comparedThe Journal of Thoracic and Cwith cells-only group or CRT-only group (P < .01 for
both comparisons). In those animals, LVEDV increased
from 58.4  4.3 to 64.6  6.6 mL (Figure 4, A).
At 12 weeks, ejection fraction was significantly greater in
the hearts treated with CRT þ cells compared with those
receiving only cells or only CRT (P< .01 for both compar-
isons). In those animals, ejection fraction was increased
from 38.8%  1.97% to 44.8%  5.97% (Figure 4, B).
Wall thickening was determined by echocardiography in
the thinnest region of the infarct area 4 and 12 weeks after
myocardial injury. At baseline, anterior wall thickness at
diastolic phase did not differ among groups. Transplantation
of cells and CRT caused an increase in diastolic wall thick-
ening in the infarcted zone relative to cells-only and
CRT-only groups (P< .01 for all; Figure 4, C).
Identification of Implanted Cells
Macroscopically, at 12 weeks, a local area of necrosis was
consistently observed in the apex and anterolateral LV wall
of all animals (Figure 2). Histological analysis with hema-
toxylin and eosin stain showed infarcted areas characterized
by the replacement of healthy myocardium by adipose and
fibrous tissue. The myocardial scars in sheep are predomi-
nantly infiltrated by adipose tissue.
By immunohistochemical analysis, sections from sheep
treated with cells were positively stained with myosin heavy
chain (the skeletal isoform of adult fast myosin heavy chain),
and satellite cells were detected (Figure 5, A). This antibody
did not react with healthy or ischemic cardiac sections. In 4
sheep of group 4 (pacingþ cell), elongated skeletal muscle
cells structures were observed that resembled multinucleated
well-differentiated myotubes (Figure 5, B), and slow twitch
type I fibers were identified across the sections. No skeletal
muscle cells were found in the healthy myocardium. By
fluorescence microscopy, satellite cells and myotubes were
detected with their nucleus marked with DAPI stain, with
better organization and greater number when comparing
group 2 (cells) versus group 4 (pacingþ cells) (Figures 6
and 7).
DISCUSSION
The prevalence of severe heart failure and the clear clin-
ical limitations of conventional interventions have encour-
aged the development of new therapeutic tools.14,15 TheE
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LVEDV (mL) LVAWd (mm) EF (%)
Groups Preischemic 4 wk 12 wk Preischemic 4 wk 12 wk Preischemic 4 wk 12 wk
Control 50  2.9 59.5  6.3 82  7.6 6.7  0.8 5.32  0.9 3.1  2.0 68.3  2.2 39  1.8 34.8  3.5
Cells 49  3.1 56.4  4.6 74.6  7.1 6.5  1.1 5.82  1.1 3.9  1.8 67.4  1.5 39.7  2 42.3  4.3
CRT 51  2.3 57.1  3.6 72.5  3.9 7.1  0.9 5.74  1.2 3.3  1.7 70.1  1.3 38.8  1.7 41.8  4.7
CRTþcells 48  3.0 58.4  4.3 64.6  6.6 6.8  0.7 5.6  1.1 5.4  1.9 68  1.9 38.8  1.97 44.8  5.97
Data are means  standard deviation. LVEDV, Left ventricular end-diastolic volume; LVAWd, anterior wall thickness at diastolic phase; EF, ejection fraction; CRT, cardiac
resynchronization therapy.ardiovascular Surgery c Volume 138, Number 4 997
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SFIGURE 4. A, Echocardiographic studies. Left ventricular end-diastolic volume (LVEDV) evolution during follow-up (*P<.01). B, Ejection fraction (EF)
evolution during follow-up (*P< .01). C, Left ventricular anterior wall thickness at diastolic phase evolution during follow-up (*P< .01). CRT, Cardiac
resynchronization therapy; LVAWd, anterior wall thickness at diastolic phase.natural evolution of heart failure with systolic function im-
pairment leads to progression of the size of cardiac
cavities. The interaction of hemodynamic processes influ-
ences this dilatation (Frank-Starling law). In cases of
highly significant increases of LV volumes, actin-myosin
cross-bridges stretch outside their physiologic limits, thus
causing a decrease—instead of an increase—of contractile
strength as well as structural changes due to the increase
of end-diastolic pressures, which accompanies dilatation.
In addition, this pathologic process involves extracardiac
mechanisms, like metabolic changes at the systemic level.
Thus, myocardial infarction leaves an akinetic fibrotic
scar, which with adverse chamber remodeling leads to
ventricular dilation and an overall loss of systolic and di-
astolic mechanical functions. Progressive LV remodeling
after myocardial infarction has been viewed as an impor-
tant contributor to progressive heart failure; an increase
in regional remodeling strain led to an increase in myocar-998 The Journal of Thoracic and Cardiovascular Surdial apoptosis and regional contractile dysfunction in heart
failure.13
Cellular therapy for myocardial regeneration in ischemic
and nonischemic cardiomyopathies is a rapidly burgeoning
field, as evidenced by the number of randomized controlled
trials of this treatment modality currently in progress or
being initiated. The idea of transplanting single cells has
a number of attractive attributes and depends on an ever-
expanding understanding of the molecular basis of
angiogenesis and myogenesis. Cellular therapy’s primary
objective is to ensure the recolonization and restoration of
postinfarction myocardial tissue, thus improving viability
and function. The initial clinical trials of cell transplantation
after a myocardial infarction have reported only limited im-
provements in ventricular function. Ongoing studies showed
survival of the implanted cells, but no study showed active
participation of the implanted cells in the force generation.
This may due to lack of electrophysiologic connectionsFIGURE 5. A, Histoimmunologic studies at 12 weeks in cell-treated group, showing isolated grafted myoblasts into the infarcted area. Stain with MY-32
antibody to skeletal myosin (original magnification,3250). B, Histoimmunologic studies at 12 weeks in the cellþelectrostimulation group, showing amixture
of multinucleated myotubes and fibrillar configuration. Stain with MY-32 antibody to skeletal myosin (original magnification, 3200).gery c October 2009
Shafy et al Evolving Technology/Basic ScienceFIGURE 6. Cross and longitudinal section of multinucleated myotubes (marked with 40,6-diamidino-2-phenylindole dye) developed in the myocardial in-
farcted area after treatment with skeletal myoblasts associated with chronic electrostimulation (original magnification, 3360).between the implanted cells and the host myocardium and
the lack of the gap junction protein (connexin 43).6,16-18
The concept of electrostimulation of homed myogenic
cells (eg, skeletal myoblasts) is to transform the passive
cells into active contracting cells, that is, from static cells
to dynamic cells. It is important to remark that the phys-
iologic myocardial cell potential is 85 mV. In our re-
search protocol, we have been delivering a 5-V pulse
from a pacemaker, with the aim to create a potential dif-
ference greater than 85 mV across each cell membrane.
Therefore, we think that ventricular wall electrostimula-
tion using 5-V pulses should induce depolarization and
contraction of the implanted stem cells. In our experimen-
tal model, ventricular walls were electrostimulated, and
therefore the transplanted skeletal myoblasts and the in-
farcted myocardium were simultaneously activated. Im-
portantly, during the postoperative evolution we did notThe Journal of Thoracic and Cobserve any animal mortality, indicating that this
approach may exclude the induction of malignant cardiac
arrhythmias related with the association of cells and elec-
trostimulation.
The principle of electrophysiologic conditioning of mus-
cle fibers, developed by our group for the latissimus dorsi
dynamic cardiomyoplasty procedure, was applied to this
experimental study.11 But in the present approach, cells
were stimulated with single pulses, not with pulse trains
(bursts containing 6 spikes) as used in cardiomyoplasty.
This was decided to avoid the risk of deleterious effects on
myoblasts.19 A functional engraftment is required to aug-
ment synchronized contractility and to avoid potentially
life-threatening alterations in the electrical conduction of
the heart. Current evidence suggests that skeletal myoblasts
or bone marrow–derived adult stem cells fail to electrome-
chanically integrate into the recipient heart with directE
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SFIGURE 7. Left, Myoblasts organized and assembled in myofibers after pacing. Stain with antibody to slow-twitch skeletal myosin (original magnification,
3300). Right, Fibrillar configuration of myoblasts marked with 40,6-diamidino-2-phenylindole dye in the infarcted area, group 4 (original magnification,
3320).ardiovascular Surgery c Volume 138, Number 4 999
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suggested that the use of electrostimulation would drive
stem cells toward differentiating into cardiac-type myogenic
cells. This type of differentiation should include the induc-
tion of gap junction formation, improving stem cell engraft-
ment and reducing the risk of arrhythmogenic events.3,20-22
A comparative study sinus node (‘‘normal’’ electrical im-
pulses) versus CRT (direct ventricular electrostimulation)
has not been done. This treatment is designed for patients
with heart failure. Most patients with heart failure present
a mechanical and/or electrical ventricular dyssynchrony, re-
sulting in increased ventricular wall stress and increased
myocardial oxygen consumption. Both are detrimental to
cell survival. These are minimized when CRT is activated
and could contribute to better cell survival.8-10 The impact
of submitting cell transplant to pulsed or static electrical
fields is not very well known and is the subject of many stud-
ies. In a previous study,23we analyzed this impact on cell cul-
tures and found that in vitro electrostimulation of cell cultures
was able to induce both morphologic and biochemical
changes in human mesenchymal stem cells, realizing a shift
toward a striated muscle cell phenotype expressing cardiac
specific markers. Remarkably, the phenotype change could
be achieved without any additional treatment or media
supplementation or coculturing conditions defining what
we could call a ‘‘clean’’method to induce cell differentiation.
Avoiding coculturing or growth factors use, issues concern-
ing change in cell immunogenicity and biosafety following
culturing conditions could be outwitted. Thus, our assump-
tion is that the combination of coordinating the tissue contrac-
tion in addition to the application of pulse electrical field
would be beneficial for the reasons exposed above. The re-
sults of the present study tend to support this hypothesis.
The effects of cell therapy on cardiac function need to be
further investigated by analyzing the active contribution of
transplanted cells to myocardial contractility, as until now
the effects of this therapy seem principally limited to stabi-
lization or reduction of ventricular dilatation (reverse remod-
eling) and improvement of myocardial viability. Cell
transplantation for heart failure still raises several questions
regarding cell delivery, cell survival, and cell injection site.
The cell injection efficiency of epicardial, endocardial, and
intracoronary cell delivery is still unknown. The low rate
of cell survival and the effects when the injections are per-
formed in the center of the infarct instead of the peri-infarct
zones warrant additional research.1,5 The development of
strategies for improving cell survival and differentiation
(eg, by using prevascularization, preconditioning proce-
dures like in vitro cell electrostimulation, cell cultures under
hypoxia conditions, combination of angiogenic and myo-
genic stem cells, and tissue engineering approaches) seems
to be of great interest.2,17,23-28
CRT is an effective therapy in symptomatic patients with
drug-refractory heart failure with prolonged QRS and low1000 The Journal of Thoracic and Cardiovascular Suejection fraction. Long-term results of CRT on exercise
tolerance and disease progression as evaluated by reversal
of maladaptive remodeling process are rather limited, mostly
reported in patients with sinus rhythm. However, it is esti-
mated that less than half of patients with heart failure have
dyssynchrony and as many as 30% of implanted patients
are considered nonresponders.29-32
Despite progressive improvement of LV function and
functional capacity induced by CRT, the long-term benefits
can be limited in patients with large postischemic myocardial
scars. In fact, it seems that the correction of conduction delays
is not enough to improve heart failure symptoms when myo-
cardial viability is severely compromised.10,32-34 For this rea-
son, we underwent studies associating cell-based myocardial
regeneration procedures with CRT. The goal was to associate
cellular cardiomyoplasty with cardiac pacing to create a
dynamic cellular cardiac support. Our hypothesis was that
the combination of CRT with cell transplantation should be
a superior treatment strategy in patients with heart failure.35
Electrostimulation of both ventricles following skeletal myo-
blast implantation seems to induce the contraction of the
transplanted cells and a higher expression of slow myosin,
which is better adapted for chronic ventricular assistance.
Large randomized studies would be useful to further confirm
our experimental results.
Limitations of the Study
The quantification of viable cells and the connections be-
tween the grafted cells and the scar area or native myocar-
dium have not been specifically evaluated. Therefore,
these particular points deserve future studies. Because in
the present study animals were evaluated at 12 weeks, future
investigations should include longer-term follow-up incor-
porating tissue Doppler imaging or another method to assess
segmental contractility, scar size, and diastolic function of
the treated ventricular wall.
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